Advanced Biomed Inc. (NASDAQ:ADVB) Shares Shorted: Short Interest Up 91.9% in September

Posted by Donna Armstrong on Oct 14th, 2026

Advanced Biomed Inc. (NASDAQ:ADVB – Get Free Report) saw a significant increase in short interest during the month of September. As of September 30th, there was short interest totaling 18,897 shares, an increase of 91.9% from the September 15th total of 9,845 shares. Based on an average daily trading volume, of 22,487 shares, the days-to-cover ratio is presently 0.8 days. Approximately 1.6% of the company’s stock are short sold.

Advanced Biomed Trading Down 2.3%

NASDAQ:ADVB opened at $5.16 on Wednesday. Advanced Biomed has a twelve month low of $3.61 and a twelve month high of $24.23. The company has a market cap of $8.51 million, a PE ratio of 1.05 and a beta of 0.01. The company’s 50 day moving average is $7.70 and its two-hundred day moving average is $6.46.

Advanced Biomed (NASDAQ:ADVB – Get Free Report) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $0.44 earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Wall Street Zen raised Advanced Biomed to a “hold” rating in a report on Saturday, August 22nd. Weiss Ratings downgraded shares of Advanced Biomed from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, October 8th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Read Our Latest Analysis on Advanced Biomed

Advanced Biomed Company Profile

(Get Free Report)

Advanced Biomed Inc is a clinical-stage biopharmaceutical company focused on developing radiopharmaceutical products for the diagnosis and treatment of cancer.

The company’s research is centered on radioligand therapies, which use targeting molecules to deliver radioactive substances directly to cancer cells. Its development programs include products designed to target prostate-specific membrane antigen (PSMA), an established target in prostate cancer.

Advanced Biomed’s programs remain subject to clinical development and regulatory review.